MedTrace Logo

Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

NCT03567304 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-07-24

No results posted yet for this study

Summary

People living with HIV in the era of antiretroviral therapy (ART) continue to suffer high rates of neurocognitive disorder. This is a randomized control trial aiming to evaluate improvement of neurocognitive function after switching efavirenz (EFV) to rilpivirine (RPV). EFV based regimen is currently the first line ART in Thailand. There are several reports suggested that HIV-infected patients who took EFV based regimen had poorer neurocognitive function compared to the comparator. RPV, another first line regimen, has been known to have less neuropsychiatric side effects. We hypothesized that switching EFV to RPV could improve neurocognitive function.

Conditions

Interventions

DRUG

Rilpivirine 25 mg

Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)

Sponsors & Collaborators

  • Chiang Mai University

    lead OTHER

Principal Investigators

  • Quanhathai Kaewpoowat, MD · Department of Medicine, Faculty of Medicine, Chiang Mai University, Thailand.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-06
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03567304 on ClinicalTrials.gov